C
CRSP icon

Covestor’s CRISPR Therapeutics CRSP Stock Holding History

Covestor’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6K Buy
110
+17
+18% +$896 ﹤0.01% 1826
2026
Q1 		$4K Sell
93
-77
-45% -$4.06K ﹤0.01% 1858
2025
Q4 		$9K Sell
170
-575
-77% -$34.4K ﹤0.01% 1616
2025
Q3 		$48K Buy
+745
New +$42.8K 0.03% 922
2023
Q1 		– Sell
-387
Closed -$16K – 2095
2022
Q4 		$16K Hold
387
– – 0.01% 1102
2022
Q3 		$25K Hold
387
– – 0.02% 939
2022
Q2 		$24K Buy
387
+95
+33% +$5.58K 0.02% 941
2022
Q1 		$18K Buy
+292
New +$18.3K 0.01% 1089

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Covestor's CRSP Position: Q2 2026 in Review

Covestor increased its CRISPR Therapeutics (CRSP) stake by 18% in Q2 2026, buying an estimated $896 and bringing the position to 110 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1826.

Covestor first reported a position in CRSP in Q1 2022 and has held it in 8 quarters since. The position peaked at $48K in Q3 2025. 386 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Covestor held 110 shares of CRISPR Therapeutics worth $6K as of Q2 2026.
  • Covestor bought 17 CRISPR Therapeutics shares in Q2 2026, an estimated $896.
  • CRISPR Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #1826 holding.
  • Covestor first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 8 quarters since.
  • Covestor's CRISPR Therapeutics position peaked at $48K in Q3 2025.
  • 386 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.